6
Oct
2022

Nobel for Bertozzi, Red Tree Eyes West Coast, & Doubling Down on Singapore

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

RevMed’s Watershed, Roivant Goes Commercial, & Roche’s Blood Test for Alzheimer’s
Moderna’s Home Run, Amylyx Bounces Back, & Enveda Advances Workout-in-a-Pill
Jazz Scoops Up Epilepsy Drug, Boulevard Aims for Immune Reset, & AbCellera Matures
Takeda Wins First-in-Class Orexin OK, Lilly’s Obesity Money Gusher, & Three New IPOs